Skip to main content
Premium Trial:

Request an Annual Quote

PathoGenetix Picks Sagentia to Develop Commercial-Scale Microbial Detection System

NEW YORK (GenomeWeb News) – Sagentia said today that it has been picked by PathoGenetix to develop a commercial scale system for rapid microbial detection and strain typing based on the Woburn, Mass.-based firm's Genome Sequence Scanning technology.

PathoGenetix plans to launch the system's first commercial application, for the research market, in late 2012.

In turning the current laboratory prototype of the GSS technology into a "technically and commercially successful platform," Sagentia said it will continue integrating state-of-the-art optics and microfluidics, making the technology more robust, improving its usability, reducing costs, and increasing manufacturing efficiency.

The GSS technology was developed with more than $50 million from the US Departments of Defense and Homeland Security and combines automated sample preparation and single molecule detection to detect and characterize microbes from complex biological samples in as little as three hours.

In November PathoGenetix said it had raised $7.5 million on top of $4 million raised in August to develop and commercialize the technology.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.